Paysign, Inc. - PAYS STOCK NEWS

Paysign, Inc. (NASDAQ: PAYS), a key player in prepaid card solutions and digital banking, announced that CEO Mark Newcomer and CFO Jeff Baker will present at the Sidoti Micro-Cap Virtual Investor Conference on August 18, 2022, at 1:00 p.m. EDT. The presentation aims to engage investors, with opportunities for one-on-one meetings. Investors can register for free at sidoti.com/events.

Paysign (NASDAQ: PAYS) reported a strong second quarter, achieving $8.6 million in revenues, up 29% from last year. The net loss decreased to $0.2 million from $0.7 million, with an Adjusted EBITDA of $0.9 million. The company added 62 plasma donation centers this quarter, totaling 437 centers. Plasma revenues increased by 31%, driven by more donations. The outlook remains optimistic, with projected full-year revenue growth of 27.5%. Despite labor shortages and some restrictions, the company anticipates continued improvements.

Paysign, Inc. (NASDAQ:PAYS) announced the resignation of co-founder Daniel H. Spence from its Board of Directors, effective August 8, 2022. He is succeeded by Matthew Lanford, the President and COO, who has extensive experience in the payments industry. CEO Mark Newcomer expressed confidence in Lanford's capabilities to enhance the board's insight. Spence contributed significantly to the company over 21 years, and the transition promises to leverage Lanford's expertise in driving future growth.

Paysign, Inc. (NASDAQ: PAYS) is set to discuss its second quarter 2022 earnings on August 9, 2022, at 5:00 p.m. Eastern time. The company specializes in prepaid card programs, patient affordability offerings, digital banking, and integrated payment processing. Paysign aims to streamline financial operations for various sectors including healthcare and retail. Participants can join via international dial-in or webcast. A replay will be available until November 11, 2022, with further details provided for financial professionals wishing to ask questions.

Paysign reported Q1 2022 revenues of $8.2 million, a 31% increase year-over-year. The net loss decreased to $0.3 million, with adjusted EBITDA rising to $0.9 million. Plasma revenue surged by 37%, driven by increased donations, while pharma revenue saw a slight decline of 9%. The company added 9 new plasma centers, totaling 375. Unrestricted cash increased by $1.1 million to $8.5 million. Full-year guidance remains unchanged, expecting revenue between $35.25 million and $38.35 million.

Paysign, Inc. (NASDAQ: PAYS) will discuss its Q1 2022 earnings on May 11, 2022, at 5:00 p.m. ET. The call will be accessible via a U.S. dial-in or an international number, and a replay will be available after the event. Paysign provides integrated payment processing, digital banking, and prepaid card programs targeting various industries, including healthcare and retail. The company aims to enhance client operations, reduce costs, and improve loyalty through its tailored solutions.

Paysign, Inc. reported a 21% increase in fourth-quarter revenues to $8.8 million and a net income of $105,000. The adjusted EBITDA rose to $1.3 million, reflecting strong growth in plasma (up 20%) and pharma revenues (up 929%). For 2021, total revenues reached $29.5 million, exceeding guidance, with a net loss improved to $2.7 million. Looking ahead, the company anticipates 2022 revenues of $35.25 million to $38.35 million, projecting 20% to 30% growth overall, with significant investment in operations.

Paysign, Inc. (NASDAQ: PAYS) will discuss its fourth-quarter and full-year 2021 earnings on March 22, 2022, at 5:00 p.m. Eastern time. The earnings call will provide insights into the company's performance in prepaid card programs, digital banking services, and integrated payment processing. Interested parties can join via dial-in or webcast. A replay of the call will be available until June 22, 2022. Paysign specializes in customized payment solutions across various sectors, aiming to streamline operations and enhance customer loyalty.

Paysign, Inc. (NASDAQ: PAYS) reported third-quarter 2021 revenues of $7.8 million, showing a year-over-year increase of $7.9 million. Plasma revenue also rose to $7.0 million, marking a 35.6% increase. The net loss narrowed to $0.3 million, translating to a diluted EPS of ($0.01). Adjusted EBITDA stood at $1.0 million, with a diluted adjusted EBITDA per share of $0.02. Transaction volumes surged, with purchase dollar volume rising 33.9% year-over-year, reflecting improved operational metrics despite ongoing pandemic challenges.